Biomarin Pharmaceutical Inc (BMRN)
81.00
-0.72
(-0.88%)
USD |
NASDAQ |
May 10, 16:00
81.00
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Price to Book Value: 3.031 for May 10, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 3.058 |
| May 08, 2024 | 3.062 |
| May 07, 2024 | 3.090 |
| May 06, 2024 | 3.072 |
| May 03, 2024 | 3.085 |
| May 02, 2024 | 3.136 |
| May 01, 2024 | 3.118 |
| April 30, 2024 | 3.022 |
| April 29, 2024 | 3.074 |
| April 26, 2024 | 3.028 |
| April 25, 2024 | 3.075 |
| April 24, 2024 | 3.413 |
| April 23, 2024 | 3.445 |
| April 22, 2024 | 3.349 |
| April 19, 2024 | 3.315 |
| April 18, 2024 | 3.369 |
| April 17, 2024 | 3.384 |
| April 16, 2024 | 3.399 |
| April 15, 2024 | 3.423 |
| April 12, 2024 | 3.449 |
| April 11, 2024 | 3.421 |
| April 10, 2024 | 3.374 |
| April 09, 2024 | 3.328 |
| April 08, 2024 | 3.264 |
| April 05, 2024 | 3.252 |
| Date | Value |
|---|---|
| April 04, 2024 | 3.25 |
| April 03, 2024 | 3.246 |
| April 02, 2024 | 3.247 |
| April 01, 2024 | 3.258 |
| March 31, 2024 | |
| March 28, 2024 | 3.347 |
| March 27, 2024 | 3.396 |
| March 26, 2024 | 3.363 |
| March 25, 2024 | 3.316 |
| March 22, 2024 | 3.245 |
| March 21, 2024 | 3.206 |
| March 20, 2024 | 3.231 |
| March 19, 2024 | 3.250 |
| March 18, 2024 | 3.194 |
| March 15, 2024 | 3.197 |
| March 14, 2024 | 3.216 |
| March 13, 2024 | 3.230 |
| March 12, 2024 | 3.246 |
| March 11, 2024 | 3.277 |
| March 08, 2024 | 3.275 |
| March 07, 2024 | 3.273 |
| March 06, 2024 | 3.306 |
| March 05, 2024 | 3.278 |
| March 04, 2024 | 3.342 |
| March 01, 2024 | 3.320 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.932
Minimum
Nov 06 2023
7.333
Maximum
Jul 20 2020
3.995
Average
3.667
Median
Mar 10 2023
Price to Book Value Benchmarks
| Pfizer Inc | 1.720 |
| Eli Lilly and Co | 56.39 |
| Ligand Pharmaceuticals Inc | 1.940 |
| Blueprint Medicines Corp | 21.50 |
| Moderna Inc | 3.508 |
Price to Book Value Related Metrics
| PE Ratio | 75.70 |
| PS Ratio | 6.341 |
| PEG Ratio | 0.4146 |
| Price to Free Cash Flow | 96.02 |
| Price | 81.00 |
| Earnings Yield | 1.32% |
| Market Cap | 15.38B |
| PEGY Ratio | 0.4146 |
| Operating PE Ratio | 88.45 |
| Normalized PE Ratio | 78.81 |